Non Small Cell Lung Cancer
Conditions
Keywords
lung cancer, intestinal microbiota, lung microbiota, surgery, chemotherapy
Brief summary
The subject is to study the lung microbiota and the one of upper airways (UAs) (much less studied than the intestinal microbiota) in 40 patients having lung cancer. 20 patients undergo only surgical treatment, while other half receives also chemotherapy. The idea is to explore changes in microbiota of the lung, upper UAs and intestine, and potentially find associations between them. These results will serve us as a base for the future study, focused on manipulation of the microbiota by prebiotics, probiotics or symbiotics and its effect on anti-cancer treatment tolerance and effectiveness.
Detailed description
Lung cancer patients will be divided in two groups, a first one with patients undergoing both chemotherapy and surgery (Pct-chir), and the second one with patients only undergoing surgery (Pchir). Following inclusion, they will be given a 7-days alimentary survey, along with blood and saliva sampling (after buccodental examination and dental panoramic). The Pct-chir group will repeat the same procedure after the chemotherapy and before the surgery. Day before the surgery, patients are asked to bring their faecal samples (in special box provided in advance) and the filled survey. During the operation the piece of lung tissue as well as the tumour (if the size enables it) will be sampled for further analysis. Lavage will be performed on the lung immediately after its resection. Saliva, faecal sample, lung and tumour tissue, and lavage will be used for bacterial DNA extraction, followed by qPCR and sequencing analysis. Lavage and blood samples will be analysed by flow cytometry and ELISA, to establish the immunological profile (interleukines, cell surface markers).
Interventions
OTHERSampling
Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
Sponsors
Université d'Auvergne
Centre Jean Perrin
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
GREENTECH SA
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Intervention model description
2 groups of patients will be follow : * Pchir : Non small cell lung carcinoma patients with an indication of immediate surgery. * Pct-chir : Non small cell lung carcinoma patients with an indication of neoadjuvant chemotherapy before the surgery.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* non small cell lung carcinoma patient suitable for surgery, or chemotherapy followed by surgery * BMI \<29.9 kg/m² * not taking antibiotics, corticosteroids and/or immunosuppressants at least during two months before inclusion * not taking prebiotics, probiotics or symbiotics at least during two months before inclusion * signing the written consent before enrollment in the study * affiliation to the national health insurance (or system alike) according to the law from 9th August 2004
Exclusion criteria
* cognitive difficulties * refusal of participation or inability to give a clear consent * digestive or pulmonary infection of a long duration during the two months preceding the study (with antibiotic treatment) * inflammatory digestive pathology * concurrent treatment with experimental medication, participation in another clinical therapeutic study within 30 days * presence of colostomy, total or partial gastrectomy * previous esophageal surgery * previous ORL (otho-rhino-laryngo) cancer treated by radiotherapy or surgery * patient enable to follow the requirements of the study * patient deprived of his rights by administrative or judicial decision
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in diversity of the lungs and upper airways microbiota | 1.5 - 4.5 months | The analysis of the diversity will be performed by DNA sequencing and qPCR on the different samples (saliva, bronchoalveolar lavage and lung tissue fragments). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect of chemotherapy on microbiota (by comparing before and after chemotherapy) | 3.5-4.5 months | Difference in the proportion of the Firmicutes phylum between UAs and lungs, and difference in the proportion of most abundant bacterial phyla between three types of samples (saliva, lung tissue, faecal samples), all analysed by qPCR and sequencing. |
| inflammatory status | 1.5 - 4.5 months | dosage of plasmatic cytokines and interleukins (ELISA or luminex) |
| effect of microbiota on pulmunary immune cells | 1.5 - 4.5 months | characterization of immune cells on lung/tumor sample and bronchoalveolar lavage fluid (flow cytometry and/or immunohistochemistry) |
Countries
France
Contacts
STUDY_DIRECTORMarie-Paule Vasson, Pr
Equipe ECREIN, CLARA, CRNH Auvergne; INRA, UMR 1019.
STUDY_DIRECTOREdith Filaire, Pr
CIAMS, Université Paris-Sud, Université Paris-Saclay, Université Orléans
STUDY_DIRECTORAnnick Bernalier-Donadille, Dr
Equipe MINHOS, UR 454 Microbiologie, INRA
STUDY_DIRECTORRea Bingula, Ph.D.
Equipe ECREIN, CLARA, CRNH Auvergne; INRA, UMR 1019
PRINCIPAL_INVESTIGATORMarc Filaire, MD, Pr
Service de Chirurgie Thoracique, Centre Jean Perrin
Outcome results
None listed